Article

Diverse somatic mutation patterns and pathway alterations in human cancers

Department of Molecular Biology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA.
Nature (Impact Factor: 41.46). 08/2010; 466(7308):869-73. DOI: 10.1038/nature09208
Source: PubMed

ABSTRACT

The systematic characterization of somatic mutations in cancer genomes is essential for understanding the disease and for developing targeted therapeutics. Here we report the identification of 2,576 somatic mutations across approximately 1,800 megabases of DNA representing 1,507 coding genes from 441 tumours comprising breast, lung, ovarian and prostate cancer types and subtypes. We found that mutation rates and the sets of mutated genes varied substantially across tumour types and subtypes. Statistical analysis identified 77 significantly mutated genes including protein kinases, G-protein-coupled receptors such as GRM8, BAI3, AGTRL1 (also called APLNR) and LPHN3, and other druggable targets. Integrated analysis of somatic mutations and copy number alterations identified another 35 significantly altered genes including GNAS, indicating an expanded role for galpha subunits in multiple cancer types. Furthermore, our experimental analyses demonstrate the functional roles of mutant GNAO1 (a Galpha subunit) and mutant MAP2K4 (a member of the JNK signalling pathway) in oncogenesis. Our study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets.

  • Source
    • "These studies have detected over 60 tumor-acquired mutations per patient. Though mutation of the p53 tumor suppressor has been identified as an almost universal characteristic (95% of ovarian tumors), all other somatic mutations have been found to occur in 3–6% of tumors or less (Kan et al, 2010; Cancer Genome Atlas Research, 2011). In combination with this diversity of somatic nucleotide variation, pervasive and recurrent copy number variation has been detected (Etemadmoghadam et al, 2009; Cancer Genome Atlas Research N, 2011), giving rise to the notion that ovarian tumor progression is driven by a " turbulent genome " . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Large-scale molecular annotation of epithelial ovarian cancer (EOC) indicates remarkable heterogeneity in the etiology of that disease. This diversity presents a significant obstacle against intervention target discovery. However, inactivation of miRNA biogenesis is commonly associated with advanced disease. Thus, restoration of miRNA activity may represent a common vulnerability among diverse EOC oncogenotypes. To test this, we employed genome-scale, gain-of-function, miRNA mimic toxicity screens in a large, diverse spectrum of EOC cell lines. We found that all cell lines responded to at least some miRNA mimics, but that the nature of the miRNA mimics provoking a response was highly selective within the panel. These selective toxicity profiles were leveraged to define modes of action and molecular response indicators for miRNA mimics with tumor-suppressive characteristics in vivo. A mechanistic principle emerging from this analysis was sensitivity of EOC to miRNA-mediated release of cell fate specification programs, loss of which may be a prerequisite for development of this disease.
    Full-text · Article · Dec 2015 · Molecular Systems Biology
  • Source
    • "Oncogenic role of PI-3 kinase p110β in prostate cancer It is conceivable that all class I PI-3 kinases are oncogenic when overexpressed or overactivated in mammalian cells [37] [58]. In human cancers , the most common gain-of-function mutations in PI3K family were from PIK3CA gene/ p110α protein, whereas the los-of-function mutations were from PTEN gene/PTEN phosphatase protein [40] [59] [60]. In a small portion of human cancers, gene amplification was seen in PIK3CB gene/p110β protein although its wild-type form is also oncogenic [58] [61]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancers in the castration-resistant stage are life-threatening because they are not curable in clinic. The novel androgen receptor inhibitor Xandi (Enzalutamide) and the new CYP17 inhibitor Zytiga (Abiraterone) prolonged patient survival only a few months in advanced prostate cancers. Therefore, novel therapeutic agents for advanced prostate cancers are urgently needed. PI-3 kinases are major intracellular signaling molecules that regulate multiple signal pathways related to cellular metabolism, cytokinesis, growth and survival. Accumulating evidence in the literature indicates that some isoforms of this kinase family are oncogenic and abnormally expressed in various human cancers, including prostate cancers. Recent extensive studies from our group and others showed that PI-3 kinase p110β is aberrantly overexpressed in advanced prostate cancers and is critical for prostate cancer development and progression as demonstrated in cell-based and animal models. Importantly, novel p110β-specific inhibitors have been developed and are currently been testing in clinical trials. In this article, we will briefly summarize recent developments in this regard.
    Full-text · Article · Nov 2014
  • Source
    • "Many GPCRs and their cognate agonists also mediate autocrine/paracrine growth stimulation in a variety of cancer cells and dramatically synergize with insulin/IGF-1 in inducing mitogenic signaling (Rozengurt, 1986). A recent characterization of cancer genomes demonstrated frequent mutations in GPCRs and G proteins (Kan et al., 2010). Consequently, we hypothesized that crosstalk between insulin/IGF-1 receptor and GPCR signaling systems is also a mechanism for enhancing the development of pancreatic cancer (Rozengurt et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is one of the most lethal human diseases. PDAC is now the fourth leading cause of cancer mortality in both men and women and deaths due to PDAC are projected to increase dramatically. Novel targets and agents for chemoprevention are urgently needed and will most likely arise from a more detailed understanding of the signaling mechanisms that stimulate the promotion and progression of sub-malignant cells into pancreatic cancer cells and from the identification of modifiable risk factors for PDAC. Many epidemiological studies have linked obesity and long-standing type 2 diabetes mellitus (T2DM) with increased risk and worse clinical outcomes for developing PDAC. These diet-related metabolic disorders are multifaceted but characterized by peripheral insulin resistance, compensatory overproduction of insulin and increased bioavailability of insulin-like growth factor-1 (IGF-1). Mounting evidence indicates that the insulin/IGF-1 receptor system plays a critical role in PDAC development and multiple studies support the notion that crosstalk between the insulin receptor and heptahelical G protein-coupled receptor (GPCR) signaling systems is an important element in the biological responses elicited by these signaling systems, including cell proliferation. This article highlights the central role of the mechanistic target of rapamycin (mTOR) in mediating crosstalk between insulin/IGF-1 and GPCR signaling in pancreatic cancer cells and proposes strategies, including the use of metformin, to target this signaling system in PDAC cells.
    Full-text · Article · Sep 2014 · Frontiers in Physiology
Show more